COMMUNIQUÉS West-GlobeNewswire

InspireMD Appoints Carotid Intervention Commercial Leader Kathleen Kennedy as Senior Vice President of Global Sales and Marketing
30/07/2026
Ms. Kennedy returns to InspireMD having previously served as Sales Director supporting the initial U.S. launch of CGuard Prime MIAMI, July 30, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the [...]
Annexon Secures Strategic Credit Facility for up to $200 Million from Oxford Finance
30/07/2026
Expands Financial Capacity as Vonaprument and Tanruprubart Programs Advance Toward Registration BRISBANE, Calif., July 30, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the [...]
Alignment Healthcare Reports Second Quarter 2026 Results, Surpassing High End of Guidance Across All Key Metrics
30/07/2026
Generates $1.3 billion in total revenue, representing 31.6% growth year-over-year Grows Medicare Advantage membership 31.5% year-over-year to approximately 294,100 members Raises the midpoint of all full-year guidance [...]
Corvus Pharmaceuticals to Provide Business Update and Second Quarter 2026 Financial Results on August 6, 2026
30/07/2026
Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT SOUTH SAN FRANCISCO, Calif., July 30, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical [...]
Keros Therapeutics to Receive Development Milestone Payment from Partner Takeda
30/07/2026
LEXINGTON, Mass., July 30, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a [...]
Praxis Precision Medicines to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026
30/07/2026
BOSTON, July 30, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced it [...]
Xenon to Report Q2 2026 Financial Results on August 6, 2026
30/07/2026
VANCOUVER, BC and BOSTON, MA, July 30, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and [...]
CapsoVision to Release Second Quarter 2026 Financial Results on August 13, 2026
30/07/2026
SARATOGA, Calif., July 30, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today announced [...]
Abivax annonce un retour positif de la FDA à l’issue de ses échanges pré-NDA concernant l’obéfazimod
30/07/2026
Abivax annonce un retour positif de la FDA à l’issue de ses échanges pré-NDA concernant l’obéfazimod La Société confirme être en bonne voie pour déposer, d’ici la fin de l’année 2026, sa première demande d’autorisation [...]
Abivax Announces Positive Pre-NDA Interaction with the FDA for Obefazimod
30/07/2026
Abivax Announces Positive Pre-NDA Interaction with the FDA for Obefazimod Company remains on track to submit its first New Drug Application for obefazimod for the treatment of moderately to severely active ulcerative [...]
Merit Medical Reports Second Quarter 2026 Results And Updates Full-Year 2026 Guidance
30/07/2026
Financial Highlights† Reported revenue of $418.8 million, up 10% Constant currency revenue* and constant currency revenue, organic* up 9% and up 9%, respectively GAAP operating margin of 14.4%, compared to 12.3% in [...]
Trevi Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 6, 2026
30/07/2026
Conference call and webcast to be held at 4:30 p.m. ET NEW HAVEN, Conn., July 30, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the [...]
Stryker reports second quarter 2026 operating results
30/07/2026
Portage, Michigan, July 30, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) reported operating results for the second quarter of 2026: Second Quarter Results Reported net sales increased 9.4% to $6.6 billion Organic net [...]
Relay Therapeutics to Announce Second Quarter 2026 Financial Results and Corporate Highlights on August 6, 2026
30/07/2026
CAMBRIDGE, Mass., July 30, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living [...]
Myriad Genetics Reports Second Quarter 2026 Financial Results; Deploying New Initiatives Focused on Driving Increased Efficiency, Productivity and Scalability
30/07/2026
Highl ights Second quarter 2026 revenue of $190.7 million decreased 11% year-over-year, reflecting a 1% decline in volume and a 9% decrease in average revenue per test year-over-year. The company is engaging payers and [...]
GenomOncology Announces Integrated End-to-End Workflow Using PacBio’s Long-Read Whole-Genome Sequencing Technology in Oncology
30/07/2026
Combined sample-to-report solution pairs PacBio HiFi WGS with GenomOncology Pathology Workbench to support clinical labs in delivering configurable, reimbursement-aligned genomic reports across tumor types CLEVELAND, [...]
CooperCompanies Announces Release Date for Third Quarter 2026
30/07/2026
SAN RAMON, Calif., July 30, 2026 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading global medical device company, announced today it will report third quarter 2026 financial results on Wednesday, September 9 [...]
INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
30/07/2026
PARIS, 30 juill. 2026 (GLOBE NEWSWIRE) -- Conformément aux articles L.233-8 II du Code de commerce et 223-16 du Règlement Général de l’Autorité des Marchés Financiers Paris, France, le 30 juillet 2026 Place de cotation [...]
Voting Rights and Shares Capital of the Company
30/07/2026
PARIS, July 30, 2026 (GLOBE NEWSWIRE) -- In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés [...]

Pages